INTERNATIONAL JOURNAL OF APPLIED PHARMACEUTICAL SCIENCES AND RESEARCH 2023-04-26T09:16:35+00:00 Editor-in-chief Open Journal Systems <div class="row"> <div class="col-md-4 text-center"><img src="/public/site/images/sjadmin/IJAPSR.jpg"></div> <div class="col-md-8"> <p>IJAPSR is a peer-reviewed, open-access journal published quarterly by Sierra Journals Publisher. The journal publishes original work like a research article, review article, case study, short communication, and letter to the editor. The journal covers various subjects related to pharmaceutical and applied sciences.</p> <p>The journal aims to promote basic research into clinical investigation and convert clinical evidence into practical knowledge. We encourage papers referring to global medical studies of human health.</p> <p>Sierra Journals Publisher is a member of Crossref, thus the journal provides digital object identifier, LOCKSS preservation for its content followed by indexing in good indexing agencies</p> <p>&nbsp;</p> </div> </div> <div class="row"> <div id="additionalHomeContent" class="col-md-12"> <p>ISSN NO: 2455-8095&nbsp;&nbsp;&nbsp;&nbsp; Doi prefix: 10.21477&nbsp;&nbsp; &nbsp;</p> &nbsp;&nbsp; <div id="myCarousel" class="carousel slide"><!-- Carousel items --> <div class="carousel-inner"> <div class="item active"> <div class="row-fluid"> <div class="col-md-3 col-xs-6"><a href="" target="_blank" rel="noopener"><img src="/public/site/images/sjadmin/logo15.png"></a></div> <div class="col-md-3 col-xs-6"><a href="" target="_blank" rel="noopener"><img src="/public/site/images/sjadmin/logo21.png"></a></div> <div class="col-md-3 col-xs-6"><a href=";q=international+journal+of+applied+pharmaceutical+sciences+and+research&amp;btnG=" target="_blank" rel="noopener"><img src="/public/site/images/sjadmin/logo31.png"></a></div> <div class="col-md-3 col-xs-6"><img src="/public/site/images/sjadmin/logo53.png"></div> </div> <!--/row-fluid--></div> <!--/item--> <div class="item"> <div class="row-fluid"> <div class="col-md-3 col-xs-6"><a href="" target="_blank" rel="noopener"><img src="/public/site/images/sjadmin/logo71.png"></a></div> <div class="col-md-3 col-xs-6"><img src="/public/site/images/sjadmin/logo83.png"></div> <div class="col-md-3 col-xs-6"><a href="" target="_blank" rel="noopener"><img src="/public/site/images/sjadmin/logo91.png"></a></div> <div class="col-md-3 col-xs-6"><img src="/public/site/images/sjadmin/logo111.png"></div> </div> <!--/row-fluid--></div> <!--/item--> <div class="item"> <div class="row-fluid"> <div class="col-md-3 col-xs-6"><a href=";searchTerm=International%20Journal%20of%20Applied%20Pharmaceutical%20Sciences%20and%20Research&amp;start=1&amp;count=10&amp;libTypeNum=0&amp;sortBy=rel" target="_blank" rel="noopener"><img src="/public/site/images/sjadmin/logo121.png"></a></div> <div class="col-md-3 col-xs-6"><a href="" target="_blank" rel="noopener"><img src="/public/site/images/sjadmin/logo131.png"></a></div> <div class="col-md-3 col-xs-6"><a href="" target="_blank" rel="noopener"><img src="/public/site/images/sjadmin/logo41.png"></a></div> </div> <!--/row-fluid--></div> <!--/item--></div> <!--/carousel-inner--> <a class="left carousel-control" href="#myCarousel" data-slide="prev">‹</a> <a class="right carousel-control" href="#myCarousel" data-slide="next">›</a></div> <!--/myCarousel--></div> </div> A Review on Peptide-based Therapeutics For Combatting COVID-19 2023-04-26T09:16:35+00:00 Anil K. Tallam Alapati Sahithi Mohana V. Nuli <p>Recent breakthroughs in peptide exploration have led to revolutionary medicinal discoveries for a number of<br>different infectious illnesses. An immediate need exists for the development of viable treatment alternatives<br>in light of the continuing danger of the COVID-19 pandemic. Peptide inhibitors have notable potential for the<br>management of developing viral infections since they are safe, effective, and selective. Antiviral peptides may<br>be rationally engineered and optimally formulated using information about the 3D structures of viral proteins<br>and the cells they target. The resultant peptides may have broad antiviral action or be extremely selective for<br>certain targets and targeted viral infections. In this article, we discuss the research done so far on severe acute<br>respiratory syndrome coronavirus 2 (SARS-CoV-2) peptide medicines. Thus far, attempts to repurpose peptide<br>medicines with antiviral and antibacterial properties have failed. Targeting the link between the SARS-CoV-2<br>spike protein and the ACE-2 (Angiotensin-Converting Enzyme-2) that initiates cellular infection and viral<br>replication has yielded the most promising discoveries, albeit by no means the only ones. While there exists no<br>approved therapy for SARS-CoV-2, the experience gained in developing peptide drugs for this virus suggests<br>that this approach may now be preferable to the use of smaller molecules.</p> 2023-04-26T00:00:00+00:00 ##submission.copyrightStatement## Assessment of the Patterns of Immunoglobulin G and M Levels in HIV Serodiscordant Couples 2023-04-26T09:00:59+00:00 Duru B. Nnamdi Meludu S. Chukwuemeka Ogbodo E. Chukwuemeka Onah C. Ejike Ehiaghe A. Friday Onyema-iloh O. Bridget Amaifeobu Clement Mbam R. Emmanuel <p>This longitudinal study assessed the patterns of immunoglobulin G and M levels in HIV serodiscordant couples. A total of<br>20 serodiscordant HIV couples (40 patients) and 20 controls (40 HIV seronegative couples) were randomly recruited for<br>the study. Five milliliters of venous blood samples were collected from each of the participants at baseline, after 6 months,<br>and after 12 months follow up period respectively for the determination of Immunoglobulin G (IgG) and Immunoglobulin<br>M (IgM) levels using immunoturbidimetric method. Results showed thatthere was a statistically significant decrease in the<br>mean serum level of IgG in the HIV discordant test group at baseline and 6 months than in the control group (p=0.000)<br>but remained similar after 12 months follow up (p=0.081). The mean serum IgM level observed in the HIV discordant test<br>group did not differ significantly (p&gt;0.05) compared to the control group at baseline, after 6 months, and 12 months follow<br>up respectively. The mean serum levels of IgG was significantly decreased in the male test group compared to male controls<br>at baseline and 6 months but were similar at 12 months whereas there were no significant differences observed in<br>serum levels of IgG in the female test groups at baseline, 6 months and 12 months follow up respectively. Furthermore, the<br>mean serum IgM levels in both the male and female test groups did not differ significantly at baseline and after 6 months<br>follow up compared with the male and female control group respectively. However, the mean serum IgM levels in the male<br>test group was significantly decreased after 12 months follow up compared with the male control group. Therefore, HIV<br>serodiscordance status may influence the serum IgG and IgM levels in affected individuals. Further studies are necessary<br>to unravel the mechanism behind these findings.</p> 2023-04-26T00:00:00+00:00 ##submission.copyrightStatement##